GRZAN Singapore Registrant and Compliance Services

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Yes. GRZAN provides overseas manufacturers with a one-stop service covering Singapore registrant holding, dealer’s licence application and holding, full product registration, change management and post-market vigilance. The Singapore system requires the registrant to be a local Singapore entity (SHARE requires CorpPass, and CorpPass is issued to locally registered entities), so overseas manufacturers must appoint a local licence holder — this is the foundation of our service, and the first gateway for overseas manufacturers entering Singapore.

Registrant holding is decoupled from distribution arrangements: changing dealers does not mean changing the registration.
Dealer licences come in importer, wholesaler and manufacturer classes.
One ASEAN CSDT dossier can support filings in multiple Southeast Asian markets.
A Malaysian registration that has passed full conformity assessment can in turn support the Singapore Abridged route (GN-15 R13).

2. Legal basis

Our service modules map onto the following regulatory nodes of the Singapore system, with the key data points as stated in the official instruments.

Service module	Regulatory / system node	Key data
Registrant holding	GN-15 R15 (October 2026); letter of authorisation on the GN-15 Annex 1 template	the registrant is listed on SMDR together with the product owner
Dealer’s licence	GN-02 R8 (effective 1 April 2026)	importer / wholesaler / manufacturer classes; 1,110 Singapore dollars per licence per year; 10 working days; valid for 12 months
Product registration	GN-15 R15; GN-17 R5 / GN-18 R5 (CSDT, October 2026)	application fee 560 Singapore dollars plus route review fee 1,000–75,600 Singapore dollars
Class A product notification	GN-15 R15 Section 3.1; GN-22 R8 (July 2025)	exempt from product registration; product notification must be completed and a licence held
Annual maintenance	GN-15 R15 Section 12	annual retention fee Class B 39 / C 67 / D 134 Singapore dollars; cancellation after 60 days overdue
Change management	GN-21 R7 (1 August 2026); GN-24 R2 (change of registrant 880 Singapore dollars / 40 working days)	at most two changes under assessment per listing
Vigilance and post-market	HSA adverse event reporting system	48 hours / 10 calendar days / 30 calendar days; final report within 30 days
UDI	GN-36 R2	Class C mandatory from 1 November 2026

3. Expert insights

Our service model is best explained by what we actually do in each module.

Module 1: registrant holding. We act as your registrant through our Singapore entity, kept decoupled from your channel arrangements — changing distributors does not require changing the registration. Through SHARE we make the submissions, respond to HSA technical queries, pay the annual retention fees and file the change notifications. Because the authorisation letter follows the GN-15 Annex 1 template, the scope of what we may do on your behalf is defined in writing from day one.

Module 2: dealer’s licence. We apply for and hold the importer licence and the wholesaler licence (including export scenarios) according to your actual business mix. We maintain QMS evidence that meets GN-02 R8 requirements, including the audit report, and keep the licences renewed annually.

Module 3: product registration. From classification determination (GN-13 R2.1 / GN-14 R3) to route argumentation (Immediate / Expedited / Abridged / Full plus Priority Review), grouping strategy (GN-12), CSDT compilation (GN-17/GN-18 R5), declaration documents (Annexes 1–4 plus the DoC), through to submission and query responses. Working to the ASEAN CSDT structure from the start keeps the dossier reusable across markets instead of rebuilt for each one, which is where most of the time saving actually comes from.

Module 4: post-market vigilance. We establish the adverse event reporting process on the three-tier timelines, the FSCA prior-notification procedure and the PSUR summarisation mechanism, and provide a unified case ledger covering every relevant Singapore entity you operate through.

Module 5: regional coordination. GRZAN operates a network of self-owned subsidiaries in Southeast Asia, covering Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines. One CSDT compilation can support multi-country filings; and a Malaysian registration that has passed full conformity assessment can in turn support the Singapore Abridged route (GN-15 R13). For manufacturers building a regional footprint, this turns each individual national approval into an asset for the next market rather than a standalone expense.

A common question is why independent licence holding matters. The table below summarises the usual concerns and how independent holding answers them.

Your concern	How independent holding addresses it
fear that the registration becomes bound to the channel partner	the registration is held by an independent body; the channel can change while the registration stays
fear of opaque progress and costs	holder services are priced separately; progress and official fee receipts are verifiable
fear that vigilance duties go unfulfilled	we build the local vigilance process and retain complete records
fear of needing to take the registration back later	the contract reserves a path for transfer to your own entity, with cooperation obligations

4. Practical recommendations

Engagements with us follow a defined sequence, so you know what happens at each step.

Needs discussion → product list, target classes, existing overseas approvals.
Route and cost estimate → four-dimension matrix (eligibility / cost / timeline / risk).
Signing and authorisation → commercial contract plus the GN-15 Annex 1 letter of authorisation.
Document preparation → CSDT master plus the Singapore adaptation layer.
Submission and responses → SHARE submission, HSA query responses (single round within 10 working days).
Certificate and maintenance → annual retention fees, change management, vigilance and PSUR.

Regulatory information verified as of: 26 October 2026
Source level: Tier 2 (GN-15 R15; GN-02 R8; GN-17/GN-18 R5; GN-21 R7; GN-24 R2; GN-36 R2; HSA fees page)

5. Verification checklist

□ The registrant is a local Singapore entity with CorpPass access
□ The dealer’s licence class matches the actual business activity
□ The annual retention fee class (39 / 67 / 134 Singapore dollars) is budgeted and paid on time
□ The change queue respects the two-under-assessment cap per listing
□ The AE reporting tiers (48 hours / 10 days / 30 days) are covered by the vigilance process
□ UDI readiness is confirmed for Class C products before 1 November 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.